Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study

被引:9
作者
Deuker, Marina [1 ,2 ]
Stolzenbach, L. Franziska [2 ,3 ]
Ruvolo, Claudia Colla [2 ,4 ]
Nocera, Luigi [2 ,5 ,6 ]
Mansour, Mila [2 ]
Tian, Zhe [2 ]
Roos, Frederik C. [1 ]
Becker, Andreas [1 ]
Kluth, Luis A. [1 ]
Tilki, Derya [3 ]
Shariat, Shahrokh F. [7 ,8 ,9 ]
Saad, Fred [2 ]
Chun, Felix K. H. [1 ]
Karakiewicz, Pierre, I [2 ]
机构
[1] Univ Hosp Frankfurt, Dept Urol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany
[2] Univ Montreal, Hlth Ctr, Div Urol, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[3] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[4] Univ Naples Federico II, Dept Urol, Naples, Italy
[5] IBCAS San Raffaele Sci Inst, Urol Res Inst, Dept Urol, URI, Milan, Italy
[6] IBCAS San Raffaele Sci Inst, Urol Res Inst, Div Expt Oncol, URI, Milan, Italy
[7] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[8] IM Sechenov First Moscow State Med Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[9] Univ Jordan, Dept Urol, Amman, Jordan
来源
EUROPEAN UROLOGY FOCUS | 2021年 / 7卷 / 06期
关键词
Bladder cancer; Variant histology; Neoadjuvant chemotherapy; NEOADJUVANT CHEMOTHERAPY; CANCER; CYSTECTOMY; VARIANT;
D O I
10.1016/j.euf.2020.08.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Stage-specific guideline recommendations are lacking for chemotherapy in micropapillary carcinoma of the urinary bladder (MCUB). Objective: To test the efficacy of stage-specific chemotherapy for MCUB. Design, setting, and participants: Within the Surveillance, Epidemiology and End Results (SEER) registry (2001-2016), we identified patients with MCUB and pure urothelial carcinoma of the urinary bladder (UCUB) of all stages. Outcome measurements and statistical analysis: Kaplan-Meier survival analyses and multivariate Cox regression models were used to determine cancer-specific mortality (CSM) in addition to power analyses. Results and limitations: Of 210 491 patients of all stages, 518 (0.2%) harboured MCUB versus 209 973 (99.8%) UCUB. Stage at presentation was invariably higher in MCUB than in UCUB patients. Of the MCUB patients, 223 (43.1%) received chemotherapy versus 42 921 (20.4%) of the UCUB patients. In MCUB patients, chemotherapy improved CSM-free survival significantly in metastatic stage (hazard ratio [HR] 0.36, p = 0.04). Longer median CSM-free survival was also associated with chemotherapy use in addition to radical cystectomy (RC) versus RC alone in non-organ-confined MCUB (HR 0.69, p = 0.2). Additional power analyses revealed an underpowered comparison. Finally, no CSM difference was recorded in organ-confined MCUB according to the use of chemotherapy in addition to RC versus RC alone (HR 0.98, p = 1). Conclusions: Stage at presentation was invariably higher in MCUB than in UCUB patients. Very important CSM reduction was associated with chemotherapy use in metastatic MCUB. A promising protective effect of perioperative chemotherapy might also be applicable to non-organ-confined MCUB, but without sufficient statistical power. Conversely, no association was recorded in organ-confined MCUB. Patient summary: Patients with micropapillary carcinoma of the urinary bladder (MCUB) present in higher tumour stages than those with urothelial carcinoma of the urinary bladder. Chemotherapy for MCUB is effective in metastatic stages, but of no beneficial effect in organ-confined stage. In not-yet-metastatic but already non-organ-confined stages, we did not have enough observations to show a statistically significant protective effect of chemotherapy. (c) 2020 Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:1332 / 1338
页数:7
相关论文
共 24 条
  • [1] Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes
    Abufaraj, Mohammad
    Foerster, Beat
    Schernhammer, Eva
    Moschini, Marco
    Kimura, Shoji
    Hassler, Melanie R.
    Preston, Mark A.
    Karakiewicz, Pierre I.
    Remzi, Mesut
    Shariat, Shahrokh F.
    [J]. EUROPEAN UROLOGY, 2019, 75 (04) : 649 - 658
  • [2] Adjuvant chemotherapy in bladder cancer patients with histological variants: time to change the approach?
    Afferi, Luca
    Zamboni, Stefania
    Baumeister, Philipp
    Mordasini, Livio
    Mattei, Agostino
    Moschini, Marco
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S280 - S282
  • [3] Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer
    Amin, Mahul B.
    Smith, Steven C.
    Reuter, Victor E.
    Epstein, Jonathan I.
    Grignon, David J.
    Hansel, Donna E.
    Lin, Oscar
    McKenney, Jesse K.
    Montironi, Rodolfo
    Paner, Gladell P.
    Al-Ahmadie, Hikmat A.
    Algaba, Ferran
    Ali, Syed
    Alvarado-Cabrero, Isabel
    Bubendorf, Lukas
    Cheng, Liang
    Cheville, John C.
    Kristiansen, Glen
    Cote, Richard J.
    Delahunt, Brett
    Eble, John N.
    Genega, Elizabeth M.
    Gulmann, Christian
    Hartmann, Arndt
    Langner, Cord
    Lopez-Beltran, Antonio
    Magi-Galluzzi, Cristina
    Merce, Jorda
    Netto, George J.
    Oliva, Esther
    Rao, Priya
    Ro, Jae Y.
    Srigley, John R.
    Tickoo, Satish K.
    Tsuzuki, Toyonori
    Umar, Saleem A.
    Van der Kwast, Theo
    Young, Robert H.
    Soloway, Mark S.
    [J]. MODERN PATHOLOGY, 2015, 28 (05) : 612 - 630
  • [4] MICROPAPILLARY VARIANT OF TRANSITIONAL-CELL CARCINOMA OF THE URINARY-BLADDER - HISTOLOGIC PATTERN RESEMBLING OVARIAN PAPILLARY SEROUS CARCINOMA
    AMIN, MB
    RO, JY
    ELSHARKAWY, T
    LEE, KM
    TRONCOSO, P
    SILVA, EG
    ORDONEZ, NG
    AYALA, AG
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (12) : 1224 - 1232
  • [5] [Anonymous], 2022, NCCN Guidelines Version 1.2022 Breast Cancer Risk Reduction
  • [6] Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
    Berg, Sebastian
    D'Andrea, David
    Vetterlein, Malte W.
    Cole, Alexander P.
    Fletcher, Sean A.
    Krimphove, Marieke J.
    Marchese, Maya
    Lipsitz, Stuart R.
    Sonpavde, Guru
    Noldus, Joachim
    Shariat, Shahrokh F.
    Kibel, Adam S.
    Quoc-Dien Trinh
    Mossanen, Matthew
    [J]. CANCER, 2019, 125 (09) : 1449 - 1458
  • [7] Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?
    Burger, Maximilian
    Kamat, Ashish M.
    McConkey, David
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 510 - 514
  • [8] Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases
    Comperat, Eva
    Roupret, Morgan
    Yaxley, John
    Reynolds, Jamie
    Varinot, Justine
    Ouzaid, Idir
    Cussenot, Olivier
    Samaratunga, Hemamali
    [J]. PATHOLOGY, 2010, 42 (07) : 650 - 654
  • [9] Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
    Grossman, HB
    Natale, RB
    Tangen, CM
    Speights, VO
    Vogelzang, NJ
    Trump, DL
    White, RWD
    Sarosdy, MF
    Wood, DP
    Raghavan, D
    Crawford, ED
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) : 859 - 866
  • [10] Micropapillary bladder cancer: Stage at presentation and treatment outcome-Analysis of 121 patients from a cancer database
    Holyoak, Joshua D.
    Panfili, Zachary
    Kiran, Ravi P.
    Pokala, Naveen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)